September 15, 2022
The University of Cincinnati Gardner Neuroscience Institute is transforming into a Learning Health System, a data-driven, patient-centered approach with the goal of measurably improving outcomes for patients with neurological disorders.
October 6, 2022
U.S. News & World Report highlighted recent research from the University of Cincinnati that supports the hypothesis that Alzheimer’s disease is caused by a decline in levels of a protein called amyloid-beta.
September 21, 2023
The University of Cincinnati's Joseph Broderick, MD, recently joined the Know Stroke Podcast to discuss the current state of stroke research, including the FASTEST trial he is leading to test a potential treatment for strokes caused by ruptured blood vessels in the brain.
September 22, 2023
Drugs.com and HealthDay highlighted University of Cincinnati research recently published in JAMA that found using blood pressure medications to lower the top number of blood pressure readings (systolic blood pressure) may not be safe or effective among people who have an acute ischemic stroke and undergo a successful mechanical clot removal.
February 10, 2023
The University of Cincinnati's Eva Mistry presented research that found using medications to lower systolic blood pressure immediately after mechanical clot removal for acute ischemic stroke may not be safe or effective at the International Stroke Conference 2023.
October 30, 2023
The University of Cincinnati Gardner Neuroscience Institute has been renewed as the National Coordinating Center of the National Institutes of Health StrokeNet, overseeing all NIH-funded adult and pediatric stroke trials nationwide.
November 15, 2023
Clinical Research News highlighted recommendations to improve recruitment in acute stroke trials, led by UC's Joseph Broderick, following the Stroke Treatment Academic Industry Roundtable XII earlier this year.
December 8, 2023
The University of Cincinnati's Pooja Khatri and Eva Mistry spoke with Local 12 about the SISTER trial that will test a new drug to treat patients with strokes who are not eligible to receive traditional treatments due to timing factors or risk of complications.
December 7, 2023
The UC Gardner Neuroscience Institute has received $19 million in federal funding from the National Institutes of Health to serve as the lead center for a Phase 2 clinical trial that will study the efficacy of a new monoclonal antibody treatment for patients ineligible for currently available treatments.
February 7, 2024
University of Cincinnati neurology experts are presenting research at the International Stroke Conference 2024, Feb. 7-9 in Phoenix, Arizona.